Form 4: BioMarin Pharmaceutical Inc. Executive Sells Shares

Henry J. Fuchs, President of Worldwide R&D at BioMarin Pharmaceutical Inc., sold 35,341 shares of common stock at an average price of $85.1814 on March 5, 2024.

Summary

• On March 5, 2024, Henry J. Fuchs, the President of Worldwide R&D at BioMarin Pharmaceutical Inc., sold 35,341 shares of the company's common stock.
• The sale was executed at a weighted average price of $85.1814 per share, with individual prices ranging from $85.01 to $85.31.
• Following the transaction, Fuchs directly owns 212,117 shares of BioMarin Pharmaceutical Inc.
• The transaction was reported on a Form 4 filing with the Securities and Exchange Commission (SEC) on March 7, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. They can be for various reasons, including diversification, tax planning, or personal financial needs. It's important to consider the context of the sale, such as the size of the sale relative to the executive's holdings and the company's overall performance.

Stakeholder Impact

• The sale of shares by a company executive could potentially influence investor sentiment, although the impact is likely to be minimal given the size of the transaction relative to the company's overall market capitalization.

Key Dates